Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
November 01, 2023 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023 07:00 ET
|
Arvinas Inc.
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors...
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023 18:07 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023 18:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant...
CLS Americas Debuts Mobile Service Program for Office-Based Focal Laser Ablation at Western Section AUA Meeting
October 03, 2023 07:00 ET
|
Clinical Laserthermia Systems Americas, Inc.
CLS Americas Debuts Mobile Service Program for Office-Based Focal Laser Ablation at Western Section AUA Meeting
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
September 07, 2023 04:25 ET
|
Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Global Precision Oncology Research Report 2023: A Projected $225+ Billion Industry by 2031 - Explore Precision Oncology's Rise
September 04, 2023 05:28 ET
|
Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Precision Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global precision...
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Global Oncology Devices Research Report 2022-2023 & 2029 - Enhanced Reimbursement Policies Fostering Demand Growth
August 28, 2023 05:43 ET
|
Research and Markets
Dublin, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Oncology Devices Market (2023 Edition): Analysis By Device Type (Ablation, Embolization, Others), Cancer Type (Breast, Uterine, Colon and...